Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODS director wanted

This article was originally published in The Tan Sheet

Executive Summary

FDA is seeking a candidate with a medical degree and an "advanced knowledge of epidemiology, public health issues related to drug safety, and risk management" to fill the position of Office of Drug Safety director, the agency announces June 28. Job responsibilities include implementing policies and initiatives related to adverse drug events and the Medwatch program, FDA notes. The ODS director position has not been permanently filled since former director Victor Raczkowski, MD, announced his departure in October 2003. Since then, FDA Emergency Preparedness Officer Ralph Lillie has been serving as acting director. FDA announced in November it would widen its search to fill the position as part of a multi-pronged initiative on drug safety (1"The Tan Sheet" Nov. 8, 2004, p. 3)...

You may also be interested in...



FDA Office Of Drug Safety Director Is Surveillance Division Head Dal Pan

FDA is turning to five-year agency veteran Gerald Dal Pan to permanently fill the high-profile role of Office of Drug Safety director

FDA Drug Safety Process Subject To IoM Review Under Agency Initiative

FDA will sponsor an Institute of Medicine study of the agency's drug safety process as part of a broad initiative to strengthen the pre- and post-market evaluation of drugs

Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel